Innowave MTB/RIF/INH facilitates timely and accurate diagnosis of multiple-drug resistant tuberculosis as a near POCT technique: a multicenter prospective on-site performance evaluation study.

Fen Wang, Long Cai, Zhongfeng Cui, Guanglu Jiang, Hairong Huang

Abstract readMulticenter Study

In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

An evaluation of Innowave MTB/RIF/INH assay versus Xpert MTB/RIF for rapid identification ofMicrobiology spectrum · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fen Wang *National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beiguan St No. 9, Beijing, 101149, China.

Long Cai *Medical Laboratory Center, Hangzhou Red-Cross Hospital, Hangzhou, Zhejiang Province, China.

Zhongfeng Cui *Clinical Laboratory, The Sixth People's Hospital of Zhengzhou, Zhengzhou, Henan Province, China.

Guanglu JiangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beiguan St No. 9, Beijing, 101149, China. guanglu0725@126.com.

Hairong HuangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beiguan St No. 9, Beijing, 101149, China. nclhuang@ccmu.edu.cn.

Funding

Beijing Public Health Experts Project G2023-2-002, G2022-2-010R&D Program of Beijing Municipal Education Commission KZ20231002545The National Key Research and Development Program of China 2022YFC2305203

6 · The paper itself

Abstract

backgroundMany rifampicin (RIF)-resistant (RR) tuberculosis (TB) patients remain sensitive to isoniazid (INH), which challenges the strategy of using RR as an instant indicator of multiple-drug resistance tuberculosis (MDR-TB). A molecular test capable of concurrently detecting RIF and INH resistance is urgently needed.

methodsThe performance of a novel rapid molecular test, Innowave MTB/RIF/INH (InnowaveDX) was evaluated prospectively in three tertiary hospitals. Its capability of detecting resistance to RIF and INH was assessed.

resultsIn 767 pulmonary tuberculosis (PTB) patients, InnowaveDX showed significantly higher sensitivity than the Xpert MTB/RIF assay (Cepheid, USA) (74.97% versus 68.18%; p = 0.003, χ

conclusionInnowaveDX is an easy, rapid, and sensitive molecular test for PTB diagnosis that can detect INH and RIF resistance within 3 h, facilitating MDR-TB diagnosis on the first day of hospital admission.

Indexed as

Antitubercular AgentsIsoniazidMolecular Diagnostic TechniquesMycobacterium tuberculosisRifampinTuberculosis, Multidrug-ResistantAdultDrug Resistance, Multiple, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedProspective StudiesSensitivity and SpecificityTuberculosis, PulmonaryAntitubercular AgentsIsoniazidRifampinDiagnosisDrug resistanceIsoniazidMDRRifampicinTuberculosis

Identifiers

PMID41013621

DOI10.1186/s12941-025-00822-7

PMCPMC12465834

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.